Seroprevalence of Natural and Acquired Immunity against the SARS-CoV-2 Virus in a Population Cohort from Two Chilean Cities, 2020–2022

dc.contributor.authorNúñez-Franz, Loreto
dc.contributor.authorRamírez-Santana, Muriel
dc.contributor.authorRubilar, Paola
dc.contributor.authorVial, Cecilia
dc.contributor.authorApablaza, Mauricio
dc.contributor.authorGonzález, Claudia
dc.contributor.authorSaid, Macarena
dc.contributor.authorOlivares, Kathya
dc.contributor.authorCortés, Lina Jimena
dc.contributor.authorHormazábal, Juan
dc.contributor.authorCanales, Luis
dc.contributor.authorVial, Pablo
dc.contributor.authorIcaza, Gloria
dc.contributor.authorQuezada-Gaete, Rubén
dc.contributor.authorAguilera, Ximena
dc.date.accessioned2023-04-27T17:17:48Z
dc.date.available2023-04-27T17:17:48Z
dc.date.issued2023
dc.description.abstractBackground: Chile has achieved the highest coverage for vaccines against the SARS-CoV-2 virus worldwide. Objective: To assess the progression of immunity (natural and acquired by vaccine) in a cohort from two Chilean cities. Methods: Individuals (n = 386) who participated in three phases of population-based serial prevalence studies were included (2020–2021 and 2022). Presence of SARS-CoV-2 antibodies was measured in serum. Data including time of vaccination and type of vaccine received were analysed with descriptive statistics. Results: Seroprevalence was 3.6% in the first round and increased to 96.9% in the second and 98.7% in the third. In the third round, 75% of individuals who had received the basal full scheme were seropositive at 180 days or more since their last dose; 98% of individuals who received one booster dose were seropositive at 180 days or more, and 100% participants who received two boosters were seropositive, regardless of time since their last dose. Participants receiving mRNA vaccines had higher seroprevalence rates over time. Conclusions: The high vaccination coverage in Chile enabled the population to maintain high levels of antibodies. Vaccination boosters are essential to maintain immunity over time, which also depends on the type of vaccine administered.
dc.description.versionVersión publicada
dc.format.extent15 p.
dc.identifier.citationRamírez-Santana, M.; Rubilar, P.; Vial, C.; Apablaza, M.; González, C.; Said, M.; Olivares, K.; Cortés, L.J.; Hormazábal, J.; et al. Seroprevalence of Natural and Acquired Immunity against the SARS-CoV-2 Virus in a Population Cohort from Two Chilean Cities, 2020–2022. Viruses 2023, 15, 201. https://doi.org/10.3390/ v15010201
dc.identifier.doi https://doi.org/10.3390/v15010201
dc.identifier.urihttps://repositorio.udd.cl/handle/11447/7419
dc.language.isoen
dc.subjectseroprevalence
dc.subjectSeroepidemiology
dc.subjectCovid-19
dc.subjectVaccines
dc.subjectImmunity
dc.subjectAntibodies
dc.subjectChile
dc.titleSeroprevalence of Natural and Acquired Immunity against the SARS-CoV-2 Virus in a Population Cohort from Two Chilean Cities, 2020–2022
dc.typeArticle
dcterms.accessRightsAcceso abierto
dcterms.sourceViruses

Files

Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
eroprevalence of Natural and Acquired Immunity against the SARS-CoV-2 Virus in a Population Cohort from Two Chilean Cities, 2020–2022.pdf
Size:
1.3 MB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.63 KB
Format:
Item-specific license agreed upon to submission
Description: